GeoVax Labs, Inc. Operating Income Loss

• GeoVax Labs, Inc. showed an increase of +6.0% in Operating Income Loss from 2023 to 2024.
• This data is from GeoVax Labs, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2025.
• XBRL data for this metric is available from 2009 to 2024 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2017: -$548.7 thousand | Q2 2017: -$518.2 thousand | Q3 2017: -$590.3 thousand | Q1 2018: -$622.9 thousand | Q2 2018: -$638.1 thousand | Q3 2018: -$667.3 thousand | Q1 2019: -$701.6 thousand | Q2 2019: -$653.9 thousand | Q3 2019: -$425.9 thousand | Q1 2020: -$595.3 thousand | Q2 2020: -$448.1 thousand | Q3 2020: -$436.3 thousand | Q1 2021: -$1.56 million | Q2 2021: -$1.49 million | Q3 2021: -$1.95 million | Q1 2022: -$2.43 million | Q2 2022: -$2.24 million | Q3 2022: -$3.97 million | Q1 2023: -$4.27 million | Q2 2023: -$6.18 million | Q3 2023: -$8.60 million | Q1 2024: -$5.88 million | Q2 2024: -$5.06 million | Q3 2024: -$5.85 million | Q1 2025: -$5.41 million | Q2 2025: -$5.42 million | Q3 2025: -$6.37 million.
• Over the full 16 years of available data (2009 to 2024), GeoVax Labs, Inc.'s Operating Income Loss has declined by 658.4%.
• Historical annual values: Fiscal year 2024: -$25.14 million | Fiscal year 2023: -$26.74 million | Fiscal year 2022: -$14.03 million | Fiscal year 2021: -$18.75 million | Fiscal year 2020: -$2.82 million | Fiscal year 2019: -$2.37 million | Fiscal year 2018: -$2.56 million | Fiscal year 2017: -$2.17 million | Fiscal year 2016: -$3.27 million | Fiscal year 2015: -$2.69 million | Fiscal year 2014: -$2.74 million | Fiscal year 2013: -$2.29 million | Fiscal year 2012: -$2.14 million | Fiscal year 2011: -$2.35 million | Fiscal year 2010: -$2.77 million | Fiscal year 2009: -$3.32 million.
• Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: August 7, 2026